INTRODUCTION
============

Breast cancer is the most prevalent cancer that affects women worldwide. One of the most striking characteristics of this disease is the heterogeneity of its genetic and pathological aspects ([@b1-cln_67p1181]). Genomic instability is one of the hallmarks of cancerous tissues, and it increases in advanced and more aggressive tumors ([@b2-cln_67p1181],[@b3-cln_67p1181]). This instability may involve large chromosomal alterations, such as chromosomal deletions or duplications, and lead to allelic loss or amplification. In addition to the epigenetic mechanisms, the loss of heterozygosity (LOH), which results in allelic imbalance, is a common method of hampering tumor suppressor gene activities during carcinogenesis. *TP53* and *RB* are good examples of tumor suppressor genes that are frequently altered by allelic imbalance ([@b3-cln_67p1181]). Short tandem repeats (STRs) or microsatellites are polymorphic regions that are widely used to analyze allelic imbalance in tumors. In breast cancer, LOH has been detected at several loci in both familial and sporadic breast cancers, with frequencies ranging between 20% and 79% ([@b4-cln_67p1181],[@b5-cln_67p1181]). Recently, Tokunaga et al. ([@b6-cln_67p1181]) studied the microsatellite instability of five randomly selected loci in Japanese primary breast cancer samples. They observed that a high frequency of LOH was associated with triple-negative and high-grade HER2 breast cancers. When the same research group specifically evaluated microsatellite instability at the BRCA1 locus, they demonstrated that LOH at this region was independently associated with disease-free survival ([@b7-cln_67p1181]). In addition to nuclear genomic instabilities, researchers have also considered mitochondrial genomic alterations as indicators of cell commitment to carcinogenesis. Although their involvement is currently not well understood, somatic mitochondrial DNA (mtDNA) mutations seem to participate in cancer development in different ways ([@b8-cln_67p1181],[@b9-cln_67p1181]). Lim et al. ([@b10-cln_67p1181]) demonstrated that mtDNA mutations in colorectal cancer might be implicated in risk factors that induce poor outcomes and tumorigenesis. Tseng et al. ([@b11-cln_67p1181]) suggested that somatic mtDNA mutations may play a critical role in breast cancer progression.

The aim of this study was to characterize nuclear instabilities and mitochondrial genomic mutations in a cohort of Brazilian sporadic breast cancer cases. We analyzed matched pairs of breast cancer and adjacent non-cancerous breast samples by genotyping 13 nuclear STR loci \[namely, D2S123, TPOX, D3S1358, D3S1611, FGA, D7S820, TH01, D13S317, D13S790, D16S539, D17S796, intron 12 BRCA1 and intron 1 TP53\] and by directly sequencing HVI and HVII mitochondrial regions. Furthermore, we performed an association analysis of the molecular findings and clinical pathological data from the cases.

PATIENTS AND METHODS
====================

Tumor samples
-------------

Tissue specimens from sporadic primary breast cancer tumors and the corresponding adjacent tumor-free areas were obtained between 2005 and 2009 from the biopsies of 64 women at the Fernandes Figueira Institute, FIOCRUZ, Rio de Janeiro, Brazil. After excision, the tissues were snap-frozen in liquid nitrogen and stored at -70^o^C. Cancer diagnosis was confirmed by histopathology. Sixty-four percent of cases were diagnosed as invasive ductal carcinoma, and 36% were classified as invasive lobular carcinoma, mucinous, or micropapillary. DNA was extracted from the tissue samples using a salting-out method (12). The DNA was quantified using ethidium bromide staining in agarose gels and UV spectrophotometry at 260 nm. The P53 and estrogen/progesterone receptor levels, which were assessed by immunohistochemistry, and the clinical-pathological data were obtained from records of the department of pathology, IFF-FIOCRUZ. The study protocol was approved by the local ethics committee.

mtDNA sequencing
----------------

Hypervariable mitochondrial DNA regions I and II (D-loop region) were sequenced using the dideoxy chain termination method (BigDye® Terminator v3.1 Cycle Sequencing Kit) and analyzed in an automated ABI310 Sequencer (Applied Biosystems, USA). All of the sequences were aligned to the Revised Cambridge Reference Sequence, accession number NC_012920. The primer pairs designed for the PCR and direct sequencing of mtDNAs are provided in Supplementary [Table 1](#t1-cln_67p1181){ref-type="table"}. The mitochondrial somatic mutation data were assessed by comparing cancerous and adjacent non-cancerous breast samples.

STR typing of nuclear DNA and *TP53* mutation detection
-------------------------------------------------------

Nuclear genomic instability was assessed by PCR analysis of 13 STR markers. The TPOX, D3S1358, FGA, D7S820, TH01, D13S317 and D16S539 loci were amplified with the fluorescent AmpFlSTR Identifiler Genotyping system according to the manufacturer\'s recommendations (Applied Biosystems, USA) and then analyzed using the automated ABI3100 Genetic Analyzer platform and GeneMapper Software (Applied Biosystem, USA). The D13S790 locus was amplified with an independent FAM-fluorescent system and analyzed using the ABI3100 Genetic Analyzer platform (Applied Biosystems, USA). The D2S123, D3S1611, D17S796, intron 12 BRCA1 and intron 1 TP53 loci were analyzed using silver nitrate staining following a 6% denaturing polyacrylamide gel electrophoresis. Nuclear genome instability was assessed by observing the allelic imbalances, which are usually identified as LOH. Supplementary [Table 1](#t1-cln_67p1181){ref-type="table"} shows the STR loci localizations and the primer sequences. When the allelic patterns differed between the matched normal and tumor DNAs, the PCRs and electrophoresis were performed twice. Eventually, the lymphocyte DNAs of patients were also genotyped and compared to normal and tumor DNAs to confirm results. In a previous study, *TP53* mutation detection was performed for exons 4-9 ([@b13-cln_67p1181]). The association analyses were performed with Fisher\'s exact test with a significance level of 95% using GraphPad® software.

RESULTS
=======

Clinical-pathological aspects of cases
--------------------------------------

To obtain all the possible noteworthy clinical-pathological data from the studied cases, the 64 patients were evaluated for age, ethnicity, histological classification, TNM, Elston grade, p53 and estrogen and progesterone receptor expression levels ([Table 1](#t1-cln_67p1181){ref-type="table"}) and Supplementary [Tables 2](#t2-cln_67p1181){ref-type="table"} and [3](#t3-cln_67p1181){ref-type="table"}). The average age of the studied patients was 53, and the ages ranged from 27 to 76 years. The ethnic classification was based on mitochondrial haplogroups. The patients were classified into three ethnic groups: African (42%), European (40%) and Asian-Amerindians (18%). Most of the cases (69%) were diagnosed as invasive ductal carcinomas (IDCs). The other histological subtypes, which represented a total of 18 cases (31%), included the following subtypes: invasive papillary carcinoma, comedocarcinoma, mucinous and medullar intraductal carcinoma. Most of the cases (75%) were classified at low or intermediate grades, although 25% were Elston grade III (high aggressiveness). Fifty percent of the cases were progesterone-positive, and 74% were estrogen-positive. In relation to the p53 tumor suppressor protein, 70% of the cases were protein-negative, and 22% were mutant ([@b13-cln_67p1181]).

Nuclear and mitochondrial genome instability
--------------------------------------------

To investigate the genomic instability of our breast cancer cases, both the nuclear and mitochondrial DNAs were analyzed. Nuclear genome instabilities were detected by analyzing the forensic CODIS-recommended STR loci (i.e., D2S123, TPOX, D3S1358, FGA, D7S820, TH01, D13S317, D16S539) and the STRs that were designed for this study (i.e., D3S1611, D13S790, D17S796, intron 12 BRCA1 and intron 1 TP53). [Figure 1](#f1-cln_67p1181){ref-type="fig"} shows an example of LOH detection at the D13S317 locus using the fluorescent Identifiler system and a silver-stained polyacrylamide gel. Approximately half of the cases displayed microsatellite instability to some extent; this instability was characterized by allelic imbalances and 41% of cases exhibited alterations in three or more loci. Among the 13 analyzed STR loci, only the D2S123 locus was stable and the D7S820 locus had the lowest frequency of instability (1%). The intron 1 TP53 and D13S317 loci were each unstable in 16% of cases. Interestingly, the D13S790 locus had the highest frequency of instability among the STR loci (36%). [Figure 2](#f2-cln_67p1181){ref-type="fig"} displays the distribution of the number of instabilities in the STR loci. Supplementary Table 4 summarizes the data that was obtained from each of the 64 cases. Regarding the mitochondrial genome analysis, 42.18% of cases had somatic mutations, most of which were at the 303-315 poly-C region (Supplementary Table 4). [Figure 3](#f3-cln_67p1181){ref-type="fig"} illustrates an example of mtDNA mutation assessed by direct sequencing.

Association with clinical-pathological aspects
----------------------------------------------

Following the determination of nuclear instabilities and mitochondrial genomic alterations, an association study with clinical-pathological aspects was performed. Interestingly, when the most frequent unstable genome region (13q31, assessed here through the microsatellite markers D13S317 and D13S790) was analyzed separately, it was statistically associated with Elston grade III (*p* = 0.0264) ([Table 1](#t1-cln_67p1181){ref-type="table"}). Furthermore, a positive association was also observed with the presence of *TP53* mutations in IDCs (*p* = 0.0207) ([Table 2](#t2-cln_67p1181){ref-type="table"}). A highly positive association with Elston grade III was also observed with the presence of somatic mtDNA mutations (*p* = 0.0041). Moreover, reinforcing their correlation with parameters of tumor aggressiveness, the mtDNA mutations were statistically associated with negative estrogen receptor expression (*p* = 0.0001) and *TP53* mutations (*p* = 0.0162). There was no correlation between the STR instabilities and the somatic mtDNA mutations.

DISCUSSION
==========

Several molecular mechanisms are involved in the formation and progression of breast carcinomas, particularly sporadic breast cancers. An important feature of breast tumor development is the characteristic but highly heterogeneous genomic instability ([@b14-cln_67p1181]). Recently, the advantageous utilization of genome-scale analysis and microarray-based gene expression profiling has stressed the complexity of breast cancer progression ([@b15-cln_67p1181],[@b16-cln_67p1181]). This study was designed and executed to provide further understanding of genomic instability in Brazilian breast cancer cases. We performed nuclear STR loci genotyping and direct sequencing of HVI and HVII mitochondrial regions of 64 matched pairs of cancerous and adjacent non-cancerous breast samples. Our main aims were to detect genomic instabilities in well-known DNA regions using selected STR loci and the mitochondrial D-loop region and to analyze their association with clinical aspects. With the results, we could expect to have a clearer understanding of local and defined genomic changes, both nuclear and mitochondrial, and their clinical consequences. Surprisingly, through the microsatellite markers D13S317 and D13S790, we found that 13q31 was the most frequent unstable genomic region. It was most apparent at the D13S790 locus, with more than 20 cases presenting LOH. When analyzed separately from the other chromosomal loci, 13q31 was shown to be statistically associated with Elston grade III in all breast tumors and with *TP53* mutations in invasive ductal carcinomas, both of which are clinical parameters of tumor aggressiveness ([@b17-cln_67p1181],[@b18-cln_67p1181]). The 13q31 locus has been described as a chromosome region that shows different genetic alterations depending on the cancer type. Genetic gains have been observed in sarcoma ([@b19-cln_67p1181]) and colorectal cancer ([@b20-cln_67p1181]). Genetic losses have also been verified in breast cancer ([@b21-cln_67p1181],[@b22-cln_67p1181]). Eiriksdottir et al. ([@b23-cln_67p1181]) analyzed chromosome 13q in detail in 139 sporadic breast tumors with 18 polymorphic microsatellite markers and identified 3 LOH target regions: 13q12-q13, 13q14 and 13q31-q34. In another study, correlations were detected between the allelic loss of the D13S1694 marker (telomeric to *BRCA2*) and both larger tumor sizes and negative estrogen receptors ([@b24-cln_67p1181]). More recently, Schwarzenbach et al. ([@b25-cln_67p1181]), studying cell-free DNA in benign and malignant breast tumor cases, noted that LOH at D13S280 and D13S159, both markers located at 13q31-33, are associated with overall and disease-free survival. In this same study, all of the analyzed markers significantly correlated with lymph node status ([@b25-cln_67p1181]). Together, these results and our results suggest the existence of a putative suppressor gene or an important regulator sequence in this region. The miR17-92 cluster (13q31.3 region) is located near the 13q31 region; the cluster consists of seven microRNAs tightly grouped within an 800 bp genomic region in the third intron of the primary transcript C13orf25. This cluster is also known as oncomir-1 because its superexpression has been demonstrated in pulmonary cancer and lymphomas ([@b26-cln_67p1181],[@b27-cln_67p1181]). However, there is some evidence of LOH in this genomic region, mainly in breast cancer, indicating that this cluster can also play a role as a tumor suppressor gene ([@b28-cln_67p1181],[@b29-cln_67p1181]). Our results reinforce the hypothesis that instability in the 13q31 region may relate to a loss of function of microRNAs in this cluster. Because most of the allelic imbalances were associated with Elston grade III, and (more importantly) 13q31 LOH was associated with *TP53* mutations in the IDC samples, we can infer that this alteration is a delayed event in breast tumor progression. We also investigated somatic mutations in the D-loop region of the mtDNA and found that 42.18% of cases were mutated, the majority at the 303-315 poly-C region. As has been described by others ([@b30-cln_67p1181],[@b31-cln_67p1181]), we could demonstrate an association between the presence of mtDNA mutations and breast tumor aggressiveness. Parameters such as high histological grade (Elston grade III), estrogen receptor-negative and *TP53* mutations were statistically associated. Kuo et al. ([@b32-cln_67p1181]) recently reported that the presence of somatic mutations in the D-loop indicates poor prognosis; however, they did not identify a correlation with the presence of *TP53* mutations in 30 pairs of tumor and non-tumor samples. The low number of samples and/or the different types of breast cancer cases could explain the difference. *TP53* and somatic mtDNA mutations have been considered to be good biomarkers of nuclear DNA damage ([@b18-cln_67p1181],[@b32-cln_67p1181]); therefore, a correlation between both genetic alterations would be expected. However, we did not identify any association between nuclear instabilities and mtDNA alterations. Alazzouzi et al. ([@b33-cln_67p1181]) also observed that mitochondrial alterations were not associated with nuclear instability in breast tumors. In a study of colorectal carcinomas, instability in the 303 poly-C region of mtDNA was not associated with nuclear microsatellite instability ([@b34-cln_67p1181]). These observations suggest an independent occurrence of both phenomena. In conclusion, although the number of the Brazilian cases evaluated in this study was not high, we could highlight an important role for instabilities at the nuclear 13q31 locus and in mtDNA in breast cancer development and prognosis.
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###### 

Nuclear STR and mtDNA primer sequences.

  Locus     Chromosomelocalization   Motif   Primer sequences                                              Amplicon(bp)
  --------- ------------------------ ------- ---------------------------------------------------- -------- --------------
  TPOX      2p23                     AATG    ACTGGCACAGAACAGGCACTTAGGGGAGGAACTGGGAACCACAGAGGTTA   **FR**   224-252
  D2S123    2p16(hMSH2)              CA      AAACAGGATGCCTGCCTTTAGGACTTTCCACCTATGGGAC             **FR**   197-227
  D3S1611   3p21(hMLH1)              CA      CCCCAAGGCTGCACTTAGCTGAGACTACAGGCATTTG                **FR**   260-268
  D3S1358   3p21                     TCTA    ACTCGAGTCCAATCTGGTTATGAAATCAACAGAGGCTTG              **FR**   97-147
  FGA       4p28                     TTTC    GCCCCATAGGTTTTGAACTCATGATTTGTCTGTAATTGCCAGC          **FR**   206-332
  D7S820    7q11                     GATA    GATTCCACATTTATCCTCATTGACATGTTGGTCAGGCTGACTATG        **FR**   215-247
  TH01      11p15                    AATG    ATTCAAAGGGTATCTGGGCTCTGGGTGGGCTGAAAAGCTCCCGATTAT     **FR**   179-203
  D13S790   13q31                    GATA    TTGAGCCAGGATGATGTGCCTTTGGGTTGTAAACGT                 **FR**   422-454
  D13S317   13q31                    TATC    ACAGAAGTCTGGGATGTGGAGCCCAAAAAGACAGACAGAA             **FR**   165-197
  D16S539   16q24                    GATA    GGGGGTCTAAGAGCTTGTAAAAAGGTTTGTGTGTGCATCTGTAAGCAT     **FR**   264-288
  BRCA1     17q(intron 12 BRCA)      TG      GGTCATGTGTTCCATTTGGGTTGAAGCAACTTTGCAATGAG            **FR**   190-270
  D17S796   17p                      CA      CAATGGAACCAAATGTGGTCAGTCCGATAATGCCAGGATG             **FR**   144-174
  TP53      17p(intron 1 TP53)       AAAAT   GCACTGACAAAACATCCCCTAGTAAGCGGAGATAGTGCCACTGT         **FR**   150-180
  HVI       mtDNA                    \-      CGCACCTACGTTCAATATTACAGGGGTGTGTGTGTGCTGGGTAGG        **FR**   364
  HVII      mtDNA                    \-      ATTACTGCCAGCCACCATGAAACGTGTGGGCTATTTAGGCTTTA         **FR**   445

F-Forward; R-Reverse.

###### 

Clinical-pathological patient data.

  Case   Age(Years)   Ethnicity[§](#tfn10-cln_67p1181){ref-type="table-fn"})   Histologicalclassification   TNM                 EG                                              ImmunohistochemistryPR ER P53         
  ------ ------------ -------------------------------------------------------- ---------------------------- ------------------- ----------------------------------------------- ------------------------------- ----- ----
  T2     52           African                                                  IDC                          pT1c pN0 (sn) pMx   I                                               +++                             +++   \-
  T4     48           African                                                  IDC                          pT1c pN0 (sn) pMx   II                                              \+                              \+    \-
  T5     53           African                                                  IDC                          pTis pN0 (sn) pMx   [\*](#tfn9-cln_67p1181){ref-type="table-fn"})   ND                              ND    ND
  T6     56           European                                                 IDC                          pT2c pN2a pMx       III                                             \-                              \-    \+
  T8     49           African                                                  IDC                          pT1c pN0 (sn) pMx   I                                               +++                             +++   \-
  T9     60           African                                                  Invasive lobular             pT2c pN0 (sn) pMx   [\*](#tfn9-cln_67p1181){ref-type="table-fn"})   \-                              +++   \-
  T10    44           AA                                                       IDC                          pT2 pN0 pMx         III                                             \-                              \-    \+
  T11    27           African                                                  Intracystic papillary        pTis pN0 pMx        [\*](#tfn9-cln_67p1181){ref-type="table-fn"})   \+                              +++   \-
  T14    54           African                                                  IDC                          pT2 pN2a pMX        II                                              \+                              +++   \-
  T15    41           African                                                  IDC                          pT1c pN0 (sn) pMx   I                                               \-                              +++   \+
  T16    48           AA                                                       IDC                          pT1c pN0 (sn) pMX   I                                               \-                              +++   \-
  T17    46           European                                                 IDC                          pT2 pN1a pMx        II                                              \-                              \-    \-
  T18    54           European                                                 IDC                          pT1c pN2a pMX       [\*](#tfn9-cln_67p1181){ref-type="table-fn"})   +++                             +++   \-
  T19    50           African                                                  Mucinous                     pT1c pN0 (sn) pMX   I                                               \-                              +++   \-
  T21    39           AA                                                       IDC                          pT1b pN0 pMX        III                                             \-                              \-    \+
  T23    55           African                                                  IDC                          pT2 pN1a pMx        I                                               +++                             +++   \-
  T25    46           European                                                 IDC                          pT1c pN0 pMX        II                                              \-                              +++   \-
  T26    60           African                                                  IDC                          pT3 pN0 pMx         III                                             \-                              \-    \-
  T27    72           African                                                  Invasive papillary           pT1c pNx pMx        II                                              \-                              \+    \-
  T28    46           European                                                 IDC                          pT1c pN0 (sn) pMx   III                                             \-                              +++   \-
  T29    70           African                                                  Invasive papillary           pT2 pN0 (sn) pMX    I                                               ++                              +++   \-
  T31    36           African                                                  Invasive micropapillary      pT2 pN1a pMx        III                                             \-                              \-    \-
  T32    50           AA                                                       IDC                          pT1c pN0 pMx        I                                               \-                              ++    \-
  T33    56           European                                                 IDC                          pT1c pN2a pMx       III                                             \-                              +++   \-
  T34    46           European                                                 IDC                          pT2 pN1a pMx        III                                             \-                              \-    \+
  T35    49           European                                                 IDC                          pT1c pN0 (sn) pMx   II                                              +++                             \-    \-
  T36    53           European                                                 IDC                          pT2 pN0 (sn) pMx    II                                              \-                              \-    \+
  T37    47           European                                                 Mucinous                     pT1c pN0 (sn) pMx   I                                               \-                              \+    \-
  T38    61           African                                                  IDC                          pT1b pN0 (sn) pMx   I                                               +++                             +++   \-
  T40    66           African                                                  IDC                          pT1c pN2 pMx        III                                             \-                              +++   \+
  T42    40           African                                                  IDC                          pT2 pN0 (sn) pMx    I                                               +++                             +++   \-
  T43    52           AA                                                       IDC                          pTis pN0 (sn) pMx   [\*](#tfn9-cln_67p1181){ref-type="table-fn"})   \-                              \-    \-
  T44    58           African                                                  IDC                          pT2 pN1a pMx        II                                              +++                             +++   \-
  T46    44           European                                                 IDC                          pT2 pN3a pMx        II                                              \-                              +++   \-
  T47    71           European                                                 IDC                          pT2 pN0 pMx         II                                              +++                             +++   \+
  T48    40           European                                                 IDC                          pT1c pN0 pMx        II                                              \-                              \-    \+
  T50    42           African                                                  Invasive lobular             pT1a pN1a pMx       [\*](#tfn9-cln_67p1181){ref-type="table-fn"})   ++                              +++   \+
  T52    40           European                                                 IDC                          pT2 pN1a pMx        II                                              ++                              +++   \-
  T53    60           European                                                 IDC                          pT1c pN1a pMx       I                                               \-                              +++   \-
  T55    40           European                                                 Invasive apocrine            pT1a pN1a pMx       [\*](#tfn9-cln_67p1181){ref-type="table-fn"})   \+                              \+    \+
  T56    74           AA                                                       IDC                          pT2 pN1a pMx        II                                              \-                              +++   \-
  T58    70           AA                                                       Invasive lobular             pT2 pN1a pMx        [\*](#tfn9-cln_67p1181){ref-type="table-fn"})   +++                             +++   \-
  T59    46           African                                                  Invasive apocrine            pT2 pN1a pMx        II                                              \-                              \-    \+
  T60    58           European                                                 IDC                          pT2 pN1a pMx        I                                               ++                              +++   \-
  T61    44           AA                                                       IDC                          pT2 pN1b1 pMx       II                                              \+                              \+    \+
  T62    76           European                                                 IDC                          pT1 pN0 pMx         II                                              \+                              \+    \-
  T63    71           African                                                  IDC                          pT1 pN1 pMx         I                                               \+                              \+    \-
  T65    53           African                                                  Invasive papillary           ND                  II                                              \-                              \+    \-
  T68    59           African                                                  Invasive micropapillary      pT2 pN3 pMx         III                                             \-                              \-    \+
  T69    72           European                                                 Invasive lobular             pT1 pN0 pMx         [\*](#tfn9-cln_67p1181){ref-type="table-fn"})   \+                              \+    \+
  T70    50           European                                                 IDC                          pT2 pN0 pMx         II                                              \+                              \+    \-
  T71    63           European                                                 Invasive lobular             pT1 pN1 pMx         [\*](#tfn9-cln_67p1181){ref-type="table-fn"})   \+                              \+    \+
  T72    68           European                                                 IDC                          pT2 pN0 pMx         III                                             \-                              \-    \+
  T73    63           African                                                  Invasive papillary           pT1 pN2 pMx         III                                             \-                              \-    \-
  T74    75           European                                                 IDC                          pT1 pN0 pMx         III                                             \-                              \-    \+
  T75    41           European                                                 IDC                          pT2 pN1 pMx         II                                              \+                              \+    \-
  T76    60           AA                                                       Invasive micropapillary      pT2 pN2 pMx         II                                              \+                              \+    \-
  T77    46           African                                                  IDC                          pT1 pN0 pMx         I                                               \+                              \+    \-
  T78    66           European                                                 IDC                          pT1 pNx pMx         II                                              \+                              \+    \-
  T80    28           AA                                                       IDC                          pTis pN0 pMx        [\*](#tfn9-cln_67p1181){ref-type="table-fn"})   \-                              \+    \+
  T81    47           African                                                  IDC                          pT2 pN0 pMx         II                                              \+                              \+    \-
  T82    69           European                                                 Invasive micropapillary      pT1 pNx pMx         II                                              \+                              \+    \-
  T83    49           African                                                  Invasive mixed type          pT2 pNx pMx         II                                              \+                              \+    \-
  T85    61           AA                                                       Invasive apocrine            pT1 pN0 pMx         II                                              \+                              \+    \-

IDC -- Invasive ductal carcinoma; TNM -- Tumor-lymph node metastasis; EG -- Elston grade; PR -- Progesterone receptor; ER -- Estrogen receptor; Protein expression: (-) negative, (+) positive - 25-50%, (++) positive - 50-75%; (+++) positive - more than 75%; ND - no data; AA - Asian-Amerindian.

Without Elston grade classification.

Ethnicity determined by mitochondrial haplogroup.

###### 

Classification of cases according to the clinical-pathological aspects (total  =  64).

  Variables                                                       Number of samplesn (%)
  --------------------------------------------------------------- -------------------------------------
  **Age (years)**                                                 
  \<4545-5555-6565-75\>75                                         14 (22)24 (37)13 (20)12 (19)1 (2)
  **Tumor size**                                                  
  T1 (≤2 cm)T2 (\> 2 cm)T3 (\> 5 cm)Tis (Carcinoma *in situ*)ND   31 (48)27 (42)1 (2)4 (6)1 (2)
  **Lymph node metastasis**                                       
  N0N1N2N3NxND                                                    33 (52)17 (26)7 (11)2 (3)4 (6)1 (2)
  **Histological subtype**                                        
  IDCInvasive LobularOthers §                                     44 (69)5 (8)15 (23)
  **Elston grade\***                                              
  IIIIII                                                          15 (28)25 (47)13 (25)
  **Progesterone receptor**                                       
  PR +PR ++PR +++PR --ND                                          18 (28)4 (6)10 (16)31 (48)1 (2)
  **Estrogen receptor**                                           
  ER +ER ++ER +++ER --ND                                          20 (31)1 (2)26 (40)16 (25)1 (2)
  **P53**                                                         
  p53+p53-ND                                                      19 (30)44 (68)1 (2)

IDC - Invasive ductal carcinoma; § Other histological subtypes - Invasive papillary, comedocarcinoma, mucinous, medullar intraductal; PR - Progesterone receptor; ER - Estrogen receptor; High levels of protein expression - +: 25-50%, ++: 50-75%, +++:\>75%; -: Normal levels or low levels of protein expression; \* Elston grade was applied only for the IDC subtype and other types of IDC; ND -- Not detected.

###### 

Unstable STR loci, mtDNA mutations and *TP53* mutation status (exons 4-9).

  Case   Unstable STR loci                                                          Mitochondrial somatic mutations     *TP53* mutation
  ------ -------------------------------------------------------------------------- ----------------------------------- -----------------
  T2     D17S796,D13S790                                                            \-                                  G245S
  T4     D13S790                                                                    \-                                  \-
  T5     D13S790                                                                    \-                                  \-
  T6     \-                                                                         303-315C (8-9) TC (6)               \-
  T8     \-                                                                         16192 CC/T                          \-
  T9     D13S790                                                                    16309 AA/G                          \-
  T10    D3S1358, D13S317, D17S796, D3S1611, BRCA1                                  303-315 C (7-8) TC (6)              R248Q
  T11    D13S790                                                                    \-                                  \-
  T14    TH01, TP53, D3S1611, D3S1358, D17S796                                      303-315 C (7-8) TC (6)              \-
  T15    \-                                                                         \-                                  \-
  T16    \-                                                                         303-315 C (7-8) TC (6)16391 GG/A    \-
  T17    \-                                                                         303-315 C (7-8) T C (6)16261 CC/T   \-
  T18    \-                                                                         \-                                  R175H
  T19    \-                                                                         303-315 C (7-8) TC (6)              H168P
  T21    FGA, D3S1358, D3S1611, D13S790                                             303-315 C (8-9) TC (6)              R273H
  T23    \-                                                                         \-                                  \-
  T25    \-                                                                         16192CC/T                           \-
  T26    TP53,FGA, D16S539, D13S317                                                 \-                                  \-
  T27    \-                                                                         \-                                  \-
  T28    \-                                                                         \-                                  \-
  T29    D16S539, D17S796                                                           146 TT/C                            \-
  T31    FGA, D13S317, TH01, BRCA1, D13S790                                         \-                                  16888delC
  T32    \-                                                                         \-                                  \-
  T33    D13S790                                                                    \-                                  16897-16911del
  T34    D13S790                                                                    303-315 C (8-9) TC (6)66 GG/T       Y234C
  T35    D13S790, D17S796, TP53                                                     \-                                  \-
  T36    \-                                                                         \-                                  \-
  T37    D13S317                                                                    \-                                  \-
  T38    TP53                                                                                                           \-
  T40    D13S317, FGA, TH01, D17S796, D3S1611, TP53, BRCA1, D3S1358, TPOX,D13S790   294 TT/C                            I195L
  T42    \-                                                                         16261CC/T                           \-
  T43    \-                                                                         303-315 C (7-8) TC (6)              \-
  T44    \-                                                                         \-                                  \-
  T46    \-                                                                         \-                                  \-
  T47    D16S539, TP53, TPOX                                                        \-                                  \-
  T48    \-                                                                         \-                                  \-
  T50    TP53                                                                       \-                                  \-
  T52    TP53,D13S317, D16S539,D13S790                                              \-                                  \-
  T53    \-                                                                         \-                                  \-
  T55    \-                                                                         294 TT/C                            W146stop
  T56    \-                                                                         \-                                  \-
  T58    \-                                                                         \-                                  \-
  T59    TP53,TH01, BRCA1, D3S1358, D16S539, D13S317, D13S790                       303-315 C (7-8) TC (6)338 CC/T      P278A
  T60    TH01,D16S539, D13S317                                                      \-                                  \-
  T61    TP53,D13S317,D13S790                                                       215 AA/G                            \-
  T62    \-                                                                         303-315 C (8-9) TC (6)              \-
  T63    \-                                                                         \-                                  \-
  T65    \-                                                                         \-                                  \-
  T68    \-                                                                         \-                                  \-
  T69    D13S790                                                                    303-315 C (7-8) TC (6)338 CC/T      \-
  T70    D13S790                                                                    \-                                  \-
  T71    D13S790                                                                    215AA/C                             \-
  T72    D7S820,TH01, D16S539, D17S796,D13S790                                      303-315 C (7-8) TC (6)              R175H
  T73    \-                                                                         \-                                  \-
  T74    D13S790                                                                    303-315 C (7-8) TC (6)16291 CC/T    \-
  T75    \-                                                                         \-                                  \-
  T76    D3S1611                                                                    303-315 C (7-8) TC                  D259V
  T77    \-                                                                         \-                                  \-
  T78    D13S790                                                                    303-315 C (7-8) TC (6)16291CC/T     \-
  T80    \-                                                                         \-                                  \-
  T81    D13S790,D13S317                                                            303-315 C (7-8) TC (6)              \-
  T82    D13S790,D16S539                                                            \-                                  \-
  T83    D13S790                                                                    \-                                  \-
  T85    \-                                                                         \-                                  \-

![Detection of LOH at the D13S317 locus. The same matched pair of samples was analyzed twice in both systems (A: Identifiler fluorescent system; and B: silver-stained polyacrylamide gel) to confirm the instability. N: normal tissue; T: tumor tissue.](cln-67-10-1181-g001){#f1-cln_67p1181}

![Distribution of STR instabilities among the loci. The D2S123 locus presented no alterations. N: number of genetic instabilities at each STR locus.](cln-67-10-1181-g002){#f2-cln_67p1181}

![Detection of the mtDNA somatic mutation (16192 CC/T) in a case of breast cancer. The arrow indicates the mutation. N: normal tissue; T: tumor tissue.](cln-67-10-1181-g003){#f3-cln_67p1181}

###### 

Clinical-pathological aspects of the cases and an association analysis of STR instabilities and mtDNA mutations (n = 64).

  Clinical-pathological            All STR instabilities        Instability at 13q31 ¤¤        Somatic mtDNA mutations [§](#tfn4-cln_67p1181){ref-type="table-fn"})                                                                   
  --------------------------- ---- ----------------------- ---- ------------------------- ---- ---------------------------------------------------------------------- ----------------------------------------------------- ---- ---- -------------------------------------------------------
  **Age (years)**                                                                                                                                                                                                                     
  \<55                        37   19                      18                             21   16                                                                                                                           22   15   
  ≥55                         27   12                      15   0.6210                    16   11                                                                     1.0000                                                15   12   0.8017
  **Ethnic group**                                                                                                                                                                                                                    
  African                     27   12                      15                             16   11                                                                                                                           18   9    
  Non-African                 37   19                      18   0.6210                    21   16                                                                     1.0000                                                19   18   0.3063
  European                    26   12                      14                             13   13                                                                                                                           15   11   
  Non-European                38   19                      19   0.8035                    24   14                                                                     0.3161                                                22   16   1.0000
  AA                          11   7                       4                              8    3                                                                                                                            4    7    
  Non-AA                      53   24                      29   0.3312                    29   24                                                                     0.3311                                                33   20   0.1792
  **Tumor size**                                                                                                                                                                                                                      
  ≤2 cm (T1)                  31   17                      14                             19   12                                                                                                                           18   13   
  \>2 cm (T2+T3)              28   11                      17   0.2994                    16   12                                                                     0.7952                                                10   18   0.1188
  **Lymph node¤**                                                                                                                                                                                                                     
  Negative                    33   15                      18                             18   15                                                                                                                           17   16   
  Positive                    26   13                      13   0.7900                    16   10                                                                     0.7900                                                11   15   0.6013
  **Histological subtype**                                                                                                                                                                                                            
  IDC                         44   21                      23                             26   18                                                                                                                           26   18   
  Others                      20   10                      10   1.0000                    11   9                                                                      0.7904                                                11   9    0.7904
  **Elston grade (n = 53)**                                                                                                                                                                                                           
  I+II                        40   22                      18                             27   13                                                                                                                           25   15   
  III                         13   4                       9    0.2021                    4    9                                                                      0.0264[\*](#tfn6-cln_67p1181){ref-type="table-fn"})   2    11   0.0041[\*\*](#tfn7-cln_67p1181){ref-type="table-fn"})
  **Progesterone receptor**                                                                                                                                                                                                           
  Positive                    32   12                      20                             18   14                                                                                                                           19   13   
  Negative                    31   19                      12   0.0793                    19   12                                                                     0.7994                                                11   20   0.0787
  **Estrogen receptor**                                                                                                                                                                                                               
  Positive                    47   24                      23                             30   17                                                                                                                           29   18   
  Negative                    16   7                       9    0.7735                    7    9                                                                      0.2397                                                1    15   0.0001[\*\*](#tfn7-cln_67p1181){ref-type="table-fn"})
  **p53**                                                                                                                                                                                                                             
  Positive                    19   7                       12                             9    10                                                                                                                           7    12   
  Negative                    44   24                      20   0.2737                    28   16                                                                     0.2721                                                23   21   0.2866
  ***TP53*mutation**                                                                                                                                                                                                                  
  WT                          50   27                      23                             32   18                                                                                                                           33   17   
  Mutant                      14   4                       10   0.1322                    5    9                                                                      0.0724                                                4    10   0.0162[\*](#tfn6-cln_67p1181){ref-type="table-fn"})

**¤¤** 13q31 region: D13S317 and D13S790 STR loci.

n - Total number of samples; S - Number of stable samples; U - Number of unstable samples; AA - Asian-Amerindian; mtDNA -- Mitochondrial DNA.

WT - Wild type; M -- Mutation; IDC - Invasive Ductal Carcinoma.

Mitochondrial alteration within the D-loop region.

**¤** Lymph node metastasis: Negative (N0); Positive (N1+N2+N3).

Fisher\'s exact test (*p*≤0.05 statistically significant).

Fisher\'s exact test (*p*≤0.05 highly statistically significant).

###### 

Association analysis of *TP53* and mtDNA mutations with STR instabilities in invasive ductal carcinoma cases (n = 44).

  Clinical-pathological                                                    All STR instabilities        Instability at 13q31¤             
  ------------------------------------------------------------------- ---- ----------------------- ---- ----------------------- ---- ---- ------------------------------------------------------
  ***TP53*** **mutation**                                                                          14                                     
  WT                                                                  35   21                                                   24   11   
  Mutant                                                              9    2                       7    0.0642                  2    7    0.0207[\*](#tfn15-cln_67p1181){ref-type="table-fn"})
  **mtDNA mutations** [§](#tfn14-cln_67p1181){ref-type="table-fn"})                                                                       
  WT                                                                  26   15                      11                           17   9    
  Mutant                                                              18   8                       10   0.5406                  9    9    0.3613

**¤**13q31region: D13S317 and D13S790 STR loci.

n -- Total number of samples; S - Number of stable samples; U - Number of unstable samples; WT - Wild Type.

Somatic mtDNA mutations within the D-loop region.

Fisher\'s exact test (P≤0.05 statistically significant).
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